Tumour response evaluation with fluorodeoxyglucose positron emission tomography: Research technique or clinical tool?

Cancer Imaging

Volumn 10, Issue SPEC. ISS. A, 2010, Pages

  Anderson, H ^a   Singh, N ^a   Miles, K ^a,b  

^a Worthing Hospital   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Fluorodeoxyglucose positron emission tomography; Tumour response

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80055065075     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.9088     Document Type: Article

References (17)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16. doi:10.1093/jnci/92.3.205. PMid:10655437. (Pubitemid 30099779)
2. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21: 2574-82. doi:10.1200/JCO .2003.01.144. PMid:12829678. (Pubitemid 46606340)
3. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Institute Trials. J Nucl Med 2006; 47: 1059-66. (Pubitemid 46939960)
4. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40: 1771-7. (Pubitemid 29523568)
5. Wormanns D, Kohl G, Klotz E, et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol 2004; 14: 86-92. doi:10.1007/s00330-003-2132-0. PMid:14615902. (Pubitemid 38181058)
6. Morgan B, Utting JF, Higginson A, Thomas AL, Steward WP, Horsfield MA. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer 2006; 94: 1420-7. doi:10.1038/sj.bjc.6603140. PMid:16670720. (Pubitemid 43772276)
7. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. doi:10.1016/S0959-8049(99) 00229-4. (Pubitemid 29512308)
8. Wieder HA, Brücher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-8. doi:10.1200/JCO.2004.07.122. PMid: 14990646. (Pubitemid 41103602)
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi:10.1016/j.ejca.2008.10.026. PMid:19097774.
10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86. doi:10.1200/JCO.2006.09.2403. PMid:17242396. (Pubitemid 350002966)
11. Bradbury I, Bonell E, Boynton J, et al. Positron emission tomography (PET) imaging in cancer management. Health Technology Assessment Report 2. Glasgow: Health Technology Board for Scotland; 2002.
12. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin-s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-61. doi:10.1200/JCO.2005.01.891. PMid:15837965. (Pubitemid 46224067)
13. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-92. doi:10.1200/JCO.2003.07.054. PMid:12663716. (Pubitemid 46606405)
14. Kim MK, Ryu JS, Kim SB, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43: 1385-91. doi:10.1016/j.ejca.2007.04 .001. PMid:17512192. (Pubitemid 46874075)
15. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11: 1112-19. doi:10.1007/s11605-007-0218-8. PMid:17623263.
16. Miles KA. PET-CT in oncology: making the most of CT. Cancer Imaging 2008; 8: S87-93. doi:10.1102/1470-7330.2008.9015. PMid:18852084.
17. Miles K, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008; 8: 81-6. doi: 10.1102/1470-7330.2008.0011. PMid:18390391. (Pubitemid 351517291)